Avaglim
Withdrawn
This medicine's authorisation has been withdrawn
rosiglitazone / glimepiride
MedicineHumanWithdrawn
Spanish is available via eTranslation, the European Commission's machine translation service.
Translate to Spanish | Important information about machine translation
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Avaglim has been withdrawn for safety reasons following a decision by the European Commission.
Product information
Latest procedure affecting product information:A20/0029
26/07/2011
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Avaglim
- Active substance
- rosiglitazone
- glimepiride
- International non-proprietary name (INN) or common name
- rosiglitazone
- glimepiride
- Therapeutic area (MeSH)
- Diabetes Mellitus, Type 2
- Anatomical therapeutic chemical (ATC) code
- A10BD04
Pharmacotherapeutic group
Drugs used in diabetesTherapeutic indication
AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.
This page was last updated on